Aliases & Classifications for Skin Atrophy

MalaCards integrated aliases for Skin Atrophy:

Name: Skin Atrophy 12 15
Atrophic Condition of Skin 12 73
Atrophoderma 12 76
Atrophy - Skin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2733
ICD10 33 L90 L90.9
NCIt 50 C35163
SNOMED-CT 68 16343004
UMLS 73 C0151514

Summaries for Skin Atrophy

MalaCards based summary : Skin Atrophy, also known as atrophic condition of skin, is related to kindler syndrome and hallermann-streiff syndrome. An important gene associated with Skin Atrophy is FERMT1 (Fermitin Family Member 1), and among its related pathways/superpathways are Cytoskeletal Signaling and Adhesion. The drugs mometasone furoate and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Atrophoderma refers to conditions involving skin... more...

Related Diseases for Skin Atrophy

Diseases related to Skin Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 kindler syndrome 31.9 FBLIM1 FERMT1
2 hallermann-streiff syndrome 31.3 GJA1 LMNA
3 calcinosis 29.3 KL LMNA
4 atrophoderma of pierini and pasini 12.6
5 atrophoderma vermiculata 12.5
6 bazex syndrome 12.2
7 follicular atrophoderma, perioral pigmented, with milia and epidermoid cysts 12.0
8 ichthyosis, congenital, autosomal recessive 11 11.5
9 flynn-aird syndrome 11.5
10 keratosis pilaris atrophicans 11.5
11 sequeiros sack syndrome 11.3
12 galloway-mowat syndrome 1 11.0
13 localized lipodystrophy 11.0
14 epidermolysis bullosa simplex, generalized, with scarring and hair loss 11.0
15 rothmund-thomson syndrome 10.9
16 rombo syndrome 10.8
17 acrogeria, gottron type 10.8
18 cutis marmorata telangiectatica congenita 10.8
19 mandibuloacral dysplasia with type a lipodystrophy 10.8
20 atypical werner syndrome 10.8
21 hypotrichosis 10.3
22 localized scleroderma 10.3
23 ichthyosis 10.2
24 ichthyosis, follicular 10.2
25 warthin tumor 10.0 CD44 HBEGF
26 ichthyosis lamellar 1 10.0
27 hypohidrosis 10.0
28 folliculitis 10.0
29 cardiomyopathy, dilated, 1e 9.9 GJA1 LMNA
30 elastosis perforans serpiginosa 9.9
31 epidermoid cysts 9.9
32 lichen sclerosus et atrophicus 9.9
33 melkersson-rosenthal syndrome 9.9
34 nevus, epidermal 9.9
35 complement component 2 deficiency 9.9
36 basal cell carcinoma 1 9.9
37 cataract 9.9
38 pseudoarthrosis 9.9
39 systemic scleroderma 9.9
40 loeys-dietz syndrome 9.9
41 acrodermatitis chronica atrophicans 9.9
42 keratosis 9.9
43 basal cell carcinoma 9.9
44 acrodermatitis 9.9
45 extramedullary plasmacytoma 9.9
46 plasmacytoma 9.9
47 hypertrichosis 9.9
48 connective tissue disease 9.9
49 lupus erythematosus 9.9
50 47,xyy 9.9

Graphical network of the top 20 diseases related to Skin Atrophy:



Diseases related to Skin Atrophy

Symptoms & Phenotypes for Skin Atrophy

MGI Mouse Phenotypes related to Skin Atrophy:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.13 CD44 EBP FERMT1 GJA1 HBEGF KL
2 homeostasis/metabolism MP:0005376 10.09 CD44 FERMT1 GJA1 HBEGF KL LMNA
3 cellular MP:0005384 10.04 CD44 FBLIM1 FERMT1 GJA1 KL LMNA
4 immune system MP:0005387 10.01 CD44 FBLIM1 FERMT1 GJA1 KL LMNA
5 hematopoietic system MP:0005397 10 CD44 EBP FBLIM1 GJA1 KL LMNA
6 integument MP:0010771 9.97 CD44 EBP FERMT1 GJA1 HBEGF KL
7 limbs/digits/tail MP:0005371 9.72 CD44 GJA1 KL LMNA MYSM1
8 muscle MP:0005369 9.65 CD44 GJA1 HBEGF KL LMNA
9 normal MP:0002873 9.63 CD44 FBLIM1 GJA1 HBEGF LMNA SAT1
10 respiratory system MP:0005388 9.35 CD44 GJA1 HBEGF KL LMNA
11 skeleton MP:0005390 9.17 CD44 FBLIM1 GJA1 HBEGF KL LMNA

Drugs & Therapeutics for Skin Atrophy

Drugs for Skin Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
3
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
4
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
9
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
10
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
11
Betamethasone Approved, Vet_approved Phase 4,Phase 1 378-44-9 9782
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
13
Zinc Approved, Investigational Phase 4 7440-66-6
14
Coal tar Approved Phase 4 8007-45-2
15
Zinc oxide Approved Phase 4 1314-13-2
16
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Not Applicable 302-79-4 5538 444795
17
Calcitriol Approved, Nutraceutical Phase 4,Phase 3 32222-06-3 5280453 134070
18 Calcineurin Inhibitors Phase 4
19 Immunologic Factors Phase 4,Phase 1,Phase 2,Not Applicable
20 Anti-Allergic Agents Phase 4
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Not Applicable
22 Dermatologic Agents Phase 4,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Not Applicable
25 Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable
27 Hormones Phase 4,Phase 3,Phase 1,Not Applicable
28 glucocorticoids Phase 4,Phase 3,Phase 1,Not Applicable
29 Triamcinolone diacetate Phase 4,Not Applicable
30 triamcinolone acetonide Phase 4,Not Applicable
31 Triamcinolone hexacetonide Phase 4,Not Applicable
32 Pharmaceutical Solutions Phase 4,Not Applicable
33 Antirheumatic Agents Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Analgesics Phase 4
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Respiratory System Agents Phase 4,Phase 1
38 Bronchodilator Agents Phase 4
39 Epinephryl borate Phase 4
40 Anti-Asthmatic Agents Phase 4,Phase 1
41 Autonomic Agents Phase 4
42 Keratolytic Agents Phase 4,Not Applicable
43 Antioxidants Phase 4
44 Radiation-Protective Agents Phase 4
45 Protective Agents Phase 4
46 EMLA Phase 4
47 Emollients Phase 4,Phase 1
48 Antihypertensive Agents Phase 4
49 Betamethasone sodium phosphate Phase 4,Phase 1
50 Betamethasone benzoate Phase 4,Phase 1

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
2 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
3 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
4 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
5 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
6 Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
7 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
8 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
9 Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis Completed NCT00733954 Phase 4 clobetasol propionate spray;clobetasol propionate ointment
10 Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis Completed NCT00988637 Phase 4 Vectical™ Ointment weekdays and Clobex® Spray weekends regimen;Clobex® Spray morning and Vectical™ Ointment evening regimen
11 Efficacy of Topical Coal Tar in Children With Atopic Dermatitis Recruiting NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
12 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
13 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis Completed NCT00658788 Phase 3 clobetasol propionate spray 0.05%;calcitriol ointment
14 Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Recruiting NCT02749656 Phase 3 0.25% Desoximetasone cream (Topoxy®);0.25% Desoximetasone cream (Topicorte®);Placebo
15 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) Recruiting NCT02608476 Phase 3 CB-03-01 cream, 1%;Vehicle cream
16 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Recruiting NCT02608450 Phase 3 CB-03-01 cream, 1%;Vehicle cream
17 A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 Unknown status NCT01670513 Phase 1, Phase 2 IDP-118 Low Strength;IDP-118 High Strength
18 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test Completed NCT02111499 Phase 1, Phase 2 LAS41004-IMP1;LAS41004 IMP2;LAS41004 IMP3;LAS41004 IMP4;LAS41004 IMP6;LAS41004 IMP5
19 Novel Compositions for Treating or Preventing Dermal Disorders Recruiting NCT03103893 Phase 1, Phase 2 Rapamycin
20 A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02355639 Phase 1 Clobetasol propionate 0.05 % ointment;Betamethasone dipropionate 0.064 % ointment;Petrolatum ointment
21 A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02392130 Phase 1 Clobetasol propionate 0.05% ointment;LEO 130852A gel 1%;LEO 130852A placebo gel
22 A Study Assessing GW870086's Potential to Cause Skin Thinning Completed NCT01381445 Phase 1 GW870086 0.2%;GW870086 2%;Clobetasol Propionate;Placebo
23 Olaparib and Radiotherapy in Head and Neck Cancer Recruiting NCT02229656 Phase 1 Olaparib
24 Study With a Topical Gel Containing TRIAC and DHEA in Subjects With Skin Atrophy Due to Glucocorticoids Not yet recruiting NCT03783988 Phase 1
25 Nonneoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound Unknown status NCT02890277 Not Applicable Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
26 The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Unknown status NCT00999869 Not Applicable Botulinum toxin type A;Triamcinolone acetonide
27 Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging Completed NCT00974480 Not Applicable Tretinoin (Rejuva-A)
28 Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser Completed NCT02416531 Not Applicable Clobetasol propionate
29 Broad Band Light With and Without Radiofrequency Microneedling for Treating Senile Purpura Active, not recruiting NCT03690375 Not Applicable

Search NIH Clinical Center for Skin Atrophy

Genetic Tests for Skin Atrophy

Anatomical Context for Skin Atrophy

MalaCards organs/tissues related to Skin Atrophy:

41
Skin, Testes, Thyroid, Tongue

Publications for Skin Atrophy

Articles related to Skin Atrophy:

(show top 50) (show all 55)
# Title Authors Year
1
Mineralocorticoid receptor blockade improves glucocorticoid-induced skin atrophy but partially ameliorates anti-inflammatory actions in an irritative model in human skin explants. ( 29178328 )
2018
2
New features of aplasia cutis congenita type 5 - Skin atrophy associated with respiratory insufficiency and multiple intestinal atresia caused by the early death of twin fetus. ( 30316734 )
2018
3
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy. ( 30410676 )
2018
4
Annular Plaques With Skin Atrophy in a Young Patient. ( 28122082 )
2017
5
Intralesional Treatment With 5-Fluorouracil and Steroid Improves Allergic Contact Dermatitis Without Causing Skin Atrophy and Rebound Lesions. ( 28338541 )
2017
6
Surgical Answer to Intralesional Steroid-Induced Skin Atrophy. ( 27870650 )
2016
7
Resveratrol Derivative-Rich Melinjo Seed Extract Attenuates Skin Atrophy in Sod1-Deficient Mice. ( 26180586 )
2015
8
Acral skin atrophy in an infant: an early clue to Kindler syndrome diagnosis. ( 25764106 )
2015
9
Topical corticosteroid-induced skin atrophy: a comprehensive review. ( 25862024 )
2015
10
Palladium and Platinum Nanoparticles Attenuate Aging-Like Skin Atrophy via Antioxidant Activity in Mice. ( 25333617 )
2014
11
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 24488534 )
2014
12
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. ( 25027750 )
2014
13
Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. ( 25229861 )
2014
14
Hyalurosome gene regulation and dose-dependent restoration of skin atrophy by retinaldehyde and defined-size hyaluronate fragments in dermatoporosis. ( 25138066 )
2014
15
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 23242470 )
2013
16
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. ( 22512680 )
2012
17
Vulvar skin atrophy induced by topical glucocorticoids. ( 22594868 )
2012
18
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy. ( 22249456 )
2012
19
Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. ( 22299648 )
2012
20
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. ( 21824195 )
2011
21
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. ( 22110776 )
2011
22
Evaluation of skin atrophy associated with linear atrophoderma of Moulin by ultrasound imaging. ( 21679833 )
2011
23
Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. ( 20051715 )
2010
24
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( 19755910 )
2009
25
Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. ( 19289104 )
2009
26
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. ( 19057668 )
2008
27
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. ( 18246695 )
2008
28
Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. ( 17123343 )
2006
29
Glucocorticoid therapy-induced skin atrophy. ( 16689857 )
2006
30
Skin atrophy caused by thiocolchicoside injections. ( 17184273 )
2006
31
Action of topical thyroid hormone analogues on glucocorticoid-induced skin atrophy in mice. ( 16571090 )
2006
32
Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. ( 17177600 )
2006
33
Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. ( 12353707 )
2002
34
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. ( 11903264 )
2002
35
Eyelid skin atrophy associated with chronic usage of ophthalmic steroid ointment, and its successful treatment with the Versapulse laser. ( 11702982 )
2001
36
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. ( 11260007 )
2001
37
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. ( 9553910 )
1998
38
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. ( 9990383 )
1998
39
Skin atrophy of the eyelid induced by topical ophthalmic corticosteroids. ( 9686858 )
1998
40
Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. ( 7894098 )
1995
41
In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. ( 8106754 )
1994
42
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. ( 8225561 )
1993
43
Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. ( 8489771 )
1993
44
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. ( 1618247 )
1992
45
Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. ( 2768567 )
1989
46
Remote skin atrophy caused by topical steroids. ( 21253139 )
1988
47
Infection and prematurity as the cause of linear skin atrophy, alopecia, anonychia, and tongue lesions? ( 3901928 )
1985
48
Linear skin atrophy, scarring alopecia, anonychia, and tongue lesion: a "new" syndrome? ( 4040704 )
1985
49
Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. ( 3888708 )
1985
50
A study of potential skin atrophy following topical application of weak corticosteroids. ( 7261664 )
1981

Variations for Skin Atrophy

Expression for Skin Atrophy

Search GEO for disease gene expression data for Skin Atrophy.

Pathways for Skin Atrophy

GO Terms for Skin Atrophy

Cellular components related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 CD44 EBP GJA1 HBEGF KL
2 apical plasma membrane GO:0016324 9.33 CD44 GJA1 KL
3 focal adhesion GO:0005925 8.92 CD44 FBLIM1 FERMT1 GJA1

Biological processes related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 8.96 CD44 MMP1
2 regulation of heart contraction GO:0008016 8.62 GJA1 HBEGF

Sources for Skin Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....